ALKS
Alkermes plc
$34.99
-1.16%
2026-05-08
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Key Fundamentals
P/E Ratio
39.90
Forward P/E
23.07
EPS (TTM)
$0.90
ROE
9.4%
Revenue Growth (YoY)
28.2%
Profit Margin
9.8%
Debt/Equity
86.23
Price/Book
3.41
Beta
0.26
Market Cap
$5.99B
Avg Volume (10D)
2.0M
Recent Breakout Signals
No recent breakout signals detected for ALKS.
Recent Price Range (60 Days)
60D High
$36.60
60D Low
$27.00
Avg Volume
2.2M
Latest Close
$34.99
Get breakout alerts for ALKS
Sign up for Breakout Scanner to receive daily notifications when ALKS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Alkermes plc (ALKS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ALKS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ALKS operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.